A micro-sized vaccine based on recombinant Lactiplantibacillus plantarum fights against SARS-CoV-2 infection via intranasal immunization

COVID-19 has globally spread to burden the medical system. Even with a massive vaccination, a mucosal vaccine offering more comprehensive and convenient protection is imminent. Here, a micro-sized vaccine based on recombinant Lactiplantibacillus plantarum (rLP) displaying spike or receptor-binding d...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Letian, Hao, Jiayi, Jiang, Yuhang, Hao, Pengfei, Gao, Yuwei, Chen, Jing, Zhang, Guoqing, Jin, Ningyi, Wang, Maopeng, Li, Chang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946889/
https://www.ncbi.nlm.nih.gov/pubmed/36852097
http://dx.doi.org/10.1016/j.apsb.2023.01.005
Descripción
Sumario:COVID-19 has globally spread to burden the medical system. Even with a massive vaccination, a mucosal vaccine offering more comprehensive and convenient protection is imminent. Here, a micro-sized vaccine based on recombinant Lactiplantibacillus plantarum (rLP) displaying spike or receptor-binding domain (RBD) was characterized as microparticles, and its safety and protective effects against SARS-CoV-2 were evaluated. We found a 66.7% mortality reduction and 100% protection with rLP against SARS-CoV-2 in a mouse model. The histological analysis showed decreased hemorrhage symptoms and increased leukocyte infiltration in the lung. Especially, rLP:RBD significantly decreased pulmonary viral loads. For the first time, our study provides a L. plantarum-vectored vaccine to prevent COVID-19 progress and transmission via intranasal vaccination.

Ejemplares similares